Literature DB >> 17979152

Predicting accrual in clinical trials with Bayesian posterior predictive distributions.

Byron J Gajewski1, Stephen D Simon, Susan E Carlson.   

Abstract

Investigators need good statistical tools for the initial planning and for the ongoing monitoring of clinical trials. In particular, they need to carefully consider the accrual rate-how rapidly patients are being recruited into the clinical trial. A slow accrual decreases the likelihood that the research will provide results at the end of the trial with sufficient precision (or power) to make meaningful scientific inferences. In this paper, we present a method for predicting accrual. Using a Bayesian framework we combine prior information with the information known up to a monitoring point to obtain a prediction. We provide posterior predictive distributions of the accrual. The approach is attractive since it accounts for both parameter and sampling distribution uncertainties. We illustrate the approach using actual accrual data and discuss practical points surrounding the accrual problem. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17979152     DOI: 10.1002/sim.3128

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  19 in total

1.  Bayesian modeling and prediction of accrual in multi-regional clinical trials.

Authors:  Yi Deng; Xiaoxi Zhang; Qi Long
Journal:  Stat Methods Med Res       Date:  2014-11-03       Impact factor: 3.021

2.  Milestone prediction for time-to-event endpoint monitoring in clinical trials.

Authors:  Fang-Shu Ou; Martin Heller; Qian Shi
Journal:  Pharm Stat       Date:  2019-02-26       Impact factor: 1.894

3.  Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot.

Authors:  Byron J Gajewski; Scott M Berry; Melanie Quintana; Mamatha Pasnoor; Mazen Dimachkie; Laura Herbelin; Richard Barohn
Journal:  Stat Med       Date:  2015-01-07       Impact factor: 2.373

4.  Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study.

Authors:  Jennifer S Li; Steven D Colan; Lynn A Sleeper; Jane W Newburger; Victoria L Pemberton; Andrew M Atz; Meryl S Cohen; Fraser Golding; Gloria L Klein; Ronald V Lacro; Elizabeth Radojewski; Marc E Richmond; L Luann Minich
Journal:  Am Heart J       Date:  2011-02       Impact factor: 4.749

5.  Bayesian accrual modeling and prediction in multicenter clinical trials with varying center activation times.

Authors:  Junhao Liu; Jo Wick; Yu Jiang; Matthew Mayo; Byron Gajewski
Journal:  Pharm Stat       Date:  2020-04-21       Impact factor: 1.894

6.  Accrual Prediction Program: A web-based clinical trials tool for monitoring and predicting accrual for early-phase cancer studies.

Authors:  Junhao Liu; Jo A Wick; Dinesh Pal Mudaranthakam; Yu Jiang; Matthew S Mayo; Byron J Gajewski
Journal:  Clin Trials       Date:  2019-08-26       Impact factor: 2.486

7.  Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors.

Authors:  Yu Jiang; Steve Simon; Matthew S Mayo; Byron J Gajewski
Journal:  Stat Med       Date:  2014-11-06       Impact factor: 2.373

8.  Prediction of accrual closure date in multi-center clinical trials with discrete-time Poisson process models.

Authors:  Gong Tang; Yuan Kong; Chung-Chou Ho Chang; Lan Kong; Joseph P Costantino
Journal:  Pharm Stat       Date:  2012-03-12       Impact factor: 1.894

9.  On the Existence of Constant Accrual Rates in Clinical Trials and Direction for Future Research.

Authors:  Byron J Gajewski; Stephen D Simon; Susan E Carlson
Journal:  Int J Stat Probab       Date:  2012-11-01

10.  A novel evaluation of optimality for randomized controlled trials.

Authors:  Jo Wick; Scott M Berry; Hung-Wen Yeh; Won Choi; Christina M Pacheco; Christine Daley; Byron J Gajewski
Journal:  J Biopharm Stat       Date:  2016-06-13       Impact factor: 1.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.